ArticleResuscitation2025
Utility of magnetic resonance spectroscopy in predicting favorable outcome in adult comatose patients following cardiac arrest.
Article in Resuscitation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- When EEG and Brain MRI Disagree After Cardiac Arrest.Neurocritical care · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
aimTo correlate brain metabolites with clinical outcomes using magnetic resonance spectroscopy (MRS) in cardiac arrest (CA) patients and assess their prognostic performance compared to quantitative apparent diffusion coefficient (ADC) maps.
methodsComatose CA patients who underwent MRI and concurrent MRS were included. PRIMARY OUTCOME: coma recovery at hospital discharge; secondary outcome: good neurological function at 6 months (Cerebral Performance Index 1-2, vs. 3-5). Six metabolites were measured in the posterior cingulate gyrus (PCG), parietal white matter, and brainstem. Mean ADC values, and percentage of voxels with ADC <450 and <650 × 10
resultsOf 94 patients, 25 (27 %) achieved coma recovery, and 22 (23 %) had a good outcome at 6 months. N-acetylaspartate/Creatine (NAA/Cr) in the PCG was most discriminative for coma recovery (median 1.29, IQR 0.21 vs. 0.86, 0.32; p-value <0.0001). NAA/Cr had the highest area under the curve for coma recovery (0.9, 95 % CI 0.84-0.96) and good outcome at 6 months (AUROC 0.88, 95 % CI 0.82-0.95), significantly outperforming all quantitative ADC measurements, except mean ADC of the PCG for the secondary outcome (adj. p-value = 0.064). Multivariable models incorporating NAA/Cr or ADC, alongside clinical and EEG variables, demonstrated improved performance compared to models with clinical and EEG variables alone, though the difference was not statistically significant. Adding MRS to established early predictors of favorable outcome increased the specificity from 67 % to 93 % at 100 % sensitivity.
conclusionMRS-derived NAA/Cr in the PCG is a valuable predictor of good outcome in comatose CA patients, outperforming quantitative ADC measurements for coma recovery. Further studies are needed to optimize MRS acquisition for multimodal neuroprognostication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.